The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver
Abstract
Background: The effectiveness of fucoxanthin (Fx) in liver diseases has been reported due to its anti-inflammatory and antifibrotic effects. Mesenchymal stem cells (MSCs)-based therapy has also been proposed as a promising strategy for liver fibrosis treatment. Recent studies have shown that the co-administration of MSCs and drugs demonstrates a pronounced effect on liver fibrosis. Aim: This study aimed to determine the therapeutic potential of placenta-derived MSCs (PD-MSCs) in combination with Fx to treat liver fibrosis and evaluate their impact on the main links of liver fibrosis pathogenesis. Methods: After PD-MSCs isolation and identification, outbred ICR/CD1 mice were divided into five groups: Control group, CCl4 group (CCl4), Fx group (CCl4+Fx), PD-MSCs group (CCl4+MSCs) and cotreatment group (CCl4+MSCs+Fx). Biochemical histopathological investigations were performed. Semiquantitative analysis of the alpha-smooth muscle actin (α-SMA+), matrix metalloproteinases (MMP-9+, MMP-13+), tissue inhibitor of matrix metalloproteinases-1 (TIMP-1+) areas, and the number of positive cells in them were studied by immunohistochemical staining. Transforming growth factor-beta (TGF-β), hepatic growth factor (HGF), procollagen-1 (COL1α1) in liver homogenate and proinflammatory cytokines in blood serum were determined using an enzyme immunoassay. Results: Compared to the single treatment with PD-MSCs or Fx, their combined administration significantly reduced liver enzyme activity, the severity of liver fibrosis, the proinflammatory cytokine levels, TGF-β level, α-SMA+, TIMP-1+ areas and the number of positive cells in them, and increased HGF level, MMP-13+, and MMP-9+ areas. Conclusion: Fx enhanced the therapeutic potential of PD-MSCs in CCl4-induced liver fibrosis, but more investigations are necessary to understand the mutual impact of PD-MSCs and Fx.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nowadays, researchers have increasingly demonstrated that combining MSC-based therapies with drugs, such as simvastatin, eugenol, imatinib, Juzentaihoto, Ferulic acid, and fucoxanthin, can improve the intervention efficacy in animal models [377–382].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [382]
Citations
Cites
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Akdis, M., Aab, A., Altunbulakli, C., Azkur, K., Costa, R. A., Crameri, R., Duan, S., Eiwegger, T., Eljaszewicz, A., Ferstl, R., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.033 · Cited by 912
TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 202
Health benefits of fucoxanthin in the prevention of chronic diseases
Bae, M., Kim, M.-B., Park, Y.-K., & Lee, J.-Y. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158618 · Cited by 190
Liu, Y.-B., & Chen, M.-K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i41.5910 · Cited by 188
TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies
Ong, C. H., Tham, C. L., Harith, H. H., Firdaus, N., & Israf, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174510 · Cited by 183
HGF/c-Met: A Key Promoter in Liver Regeneration
Zhao, Y., Ye, W., Wang, Y., & Chen, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.808855 · Cited by 183
Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases
Geervliet, E., & Bansal, R. (2020) · Cells · doi:10.3390/cells9051212 · Cited by 176
Nallagangula, K. S., Nagaraj, S. K., Venkataswamy, L., & Chandrappa, M. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0083 · Cited by 169
Cited by
Xu, Y., Zhou, X., Wang, X., Jin, Y., Zhou, L., & Ye, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116848 · Cited by 29
Wang, Z., Zhong, D., Yan, T., Zheng, Q., Zhou, E., Ye, Z., He, X.-Y., Liu, Y., Yan, J., Yuan, Y., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c19748 · Cited by 16
Xu, W., Mo, W., Han, D., Dai, W., Xu, X., Li, J., & Xu, X. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18234 · Cited by 19
Xu, Y., Wang, X.-S., Zhou, X.-L., Lu, W.-M., Tang, X.-K., Jin, Y., & Ye, J.-S. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i32.3766 · Cited by 7
Liu, Z., Ye, J., Xi, J., Li, Q., Tang, Y., Tian, Y., Wang, D., Yang, Z., & Ding, Y. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70589 · Cited by 7
“Fx inhibits the expression of profibrotic genes, further confirming its antifibrotic potential in vitro and in vivo (Kim et al. 2019; Slautin et al. 2024).”
Metadata
- Authors
- Slautin, V., Konyshev, K., Gavrilov, I., Beresneva, O., Maklakova, I., & Grebnev, D.
- Affiliations
- Ural State Medical University (RU)
- Corresponding author
- Slautin, Vasilii
- ORCID
- Venue
- Current Stem Cell Research & Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2024-12
- Volume
- 19
- Issue
- 11
- Pages
- 1484-1496
- ISSN
- 1574-888X (ISSN-L)
- OpenAlex
- W4390742355
- Cited by
- 7
- References
- 75
- Citations by year
- 2025: 4 · 2024: 3
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Stem Cell Research & Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- fucoxanthin, placenta-derived mesenchymal stem cells, liver fibrosis, carbon tetrachloride-induced liver injury, combination therapy, antifibrotic effect, alpha-smooth muscle actin, matrix metalloproteinases, TIMP-1, TGF-beta, hepatocyte growth factor, inflammatory cytokines
- MeSH terms
- Actins, Animals, Carbon Tetrachloride, Disease Models, Animal, Female, Liver, Liver Cirrhosis, Male, Mice, Inbred ICR, Placenta, Pregnancy, Transforming Growth Factor beta, Hepatocyte Growth Factor, Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9, Xanthophylls, Mesenchymal Stem Cell Transplantation, Mice, Matrix Metalloproteinase 13, Transforming Growth Factor beta1, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver. https://app.cochat.ai/papers/10.2174/011574888x279940231206100902
- The paper
- Slautin, V., Konyshev, K., Gavrilov, I., Beresneva, O., Maklakova, I., & Grebnev, D. (2024). Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver. Current Stem Cell Research & Therapy. https://doi.org/10.2174/011574888x279940231206100902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.